Evidence Spotlight: Vibroacoustic Therapy (40 Hz) & Alzheimer’s Disease

STUDY OVERVIEW

A 3-year longitudinal clinical case study investigating whether 40Hz gamma-frequency Vibroacoustic Therapy (Rhythmic Sensory Stimulation) could help maintain cognition and reduce expected cognitive decline in a woman diagnosed with Alzheimer’s disease.

STUDY DETAILS

  • Study Type: Peer-reviewed longitudinal clinical case study

  • Participants: 1 (92-year-old woman with Alzheimer’s disease)

  • Frequency Used: 40Hz gamma-frequency stimulation

  • Study Duration: 3 years

  • Session Length: Initial 45-minute clinical sessions, followed by daily in-home use

WHAT THEY DID

  • 12 intensive clinical Vibroacoustic Therapy / RSS sessions over 4 weeks

  • 40Hz full-body auditory + vibrotactile gamma stimulation

  • Initial sessions delivered in clinical setting

  • Followed by nearly daily in-home Vibroacoustic Therapy use for 3 years

  • Repeated cognitive and behavioral assessments conducted

OUTCOMES MEASURED

  • MMSE (Mini Mental State Examination)

  • SLUMS cognitive testing

  • Memory assessments

  • Behavioral observations

  • Sleep

  • Caregiver interviews

  • Functional cognition tracking

MAJOR FINDING

After 3 years, her MMSE score remained stable at 22/30.

This is particularly significant because Alzheimer’s patients typically decline approximately 3.3 MMSE points annually.

ADDITIONAL REPORTED BENEFITS

  • Maintained cognitive clarity

  • Stabilized awareness

  • Reduced behavioral dysregulation

  • Improved sleep

  • Improved short-term memory indicators

  • Reduced frustration and tantrums

  • Sustained quality of life beyond expected progression patterns

CLINICAL IMPLICATIONS

This peer-reviewed longitudinal clinical case study supports Vibroacoustic Therapy / Rhythmic Sensory Stimulation as a promising modality for helping maintain cognition and potentially reduce expected cognitive decline in Alzheimer’s disease.

WHY IT MATTERS

This research suggests frequency-specific Vibroacoustic Therapy may offer meaningful support for:

  • Alzheimer’s support

  • Cognitive maintenance

  • Caregiver support strategies

  • Neurological wellness

  • Behavioral regulation

  • Nervous system support

  • Long-term quality of life

PUBLICATION & RESEARCH ACCESS

Published in: Music & Medicine (2017)

DOI: 10.47513/mmd.v9i3.565

Full Citation: Clements-Cortes, A., Ahonen, H., Evans, M., Tang-Wai, D., Freedman, M., & Bartel, L. (2017). Can Rhythmic Sensory Stimulation Decrease Cognitive Decline in Alzheimer’s Disease? A Clinical Case Study. Music & Medicine, 9(3), 174–177.

Research Access: Official journal abstract page / publication access:

https://mmd.iammonline.com/index.php/musmed/article/view/565

Previous
Previous

Evidence Spotlight: Vibroacoustic Therapy (40 Hz) & Fibromyalgia